Centauri Therapeutics Ltd. has selected its first clinical candidate in the ABX-01 program to treat gram-negative bacterial lung infections. Based on the company’s Alphamer platform, the broad-spectrum antimicrobial peptide has been selected to treat clinically prevalent and multidrug-resistant bacterial strains.
Antibody-drug conjugate developer Duality Biotherapeutics Inc. is gearing up for a second IPO attempt this year, having filed on Feb. 27 a new prospectus on the Hong Kong Stock Exchange. Two other biotechs – Genuine Biotech Ltd. and Cloudbreak Pharma Inc. – also are having another go at a listing in Hong Kong in 2025.
Antimicrobial resistance (AMR) is predicted to cause 10 million deaths every year by 2050. Since its identification more than 50 years ago, pleuromutilin has served as a scaffold for the development of new types of antibiotics.
As U.S. regulatory uncertainty swirls around the vaccine space and health care in general, Vaxcyte Inc. stands poised for a readout of phase II infant data by the end of this quarter with VAX-24, the 24-valent pneumococcal conjugate vaccine (PCV). The San Carlos, Calif.-based firm will offer top-line safety, tolerability, and immunogenicity data, to be followed by top-line data with the booster dose by the end of this year.
Dimicare Biotech and affiliated organizations have presented the discovery and preclinical characterization of DCB-001, a trichloroacetimidamide compound being developed as a novel precision antibiotic against multidrug-resistant strains.
Antibody-drug conjugate developer Duality Biotherapeutics Inc. is gearing up for a second IPO attempt this year, having filed on Feb. 27 a new prospectus on the Hong Kong Stock Exchange. Two other biotechs – Genuine Biotech Ltd. and Cloudbreak Pharma Inc. – also are having another go at a listing in Hong Kong in 2025.
Chengdu Tetrahedral Drug Research Co. Ltd. has synthesized bicyclic derivatives acting as β-lactamase (bacterial) inhibitors reported to be useful for the treatment of bacterial infection.
The Council of Scientific and Industrial Research (India) has synthesized new benzo[de]isoquinoline-1,3-dione-based fluorophore probes acting as decaprenylphosphoryl-β-D-ribose oxidase (DprE1) (M. tuberculosis) inhibitors reported to be useful for the diagnosis and treatment of tuberculosis.
Current decolonization methods for methicillin-resistant Staphylococcus aureus (MRSA) face several challenges, including resistance development or microbiome disruption. Hypharm GmbH has presented data regarding their recombinant chimeric bacteriophage endolysin HY-133 for the potential treatment of MRSA infection. HY-133 targets S. aureus and its design combines the CHAP domain from phage K with the cell wall-binding domain of lysostaphin.
Avian influenza viruses, particularly the H5 and H7 subtypes, can cause widespread outbreaks in birds and pose a significant zoonotic risk due to their potential to mutate and develop the ability for human-to-human transmission. Researchers from the University of Muenster described the preclinical efficacy of zapnometinib, a selective MEK1/2 inhibitor, against H5N1 clade 2.3.4.4b.
RSS
